ArticleBMJ global health2017
Global investment targets for malaria control and elimination between 2016 and 2030.
Article in BMJ global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Models for malaria control optimization-a systematic review.Malaria journal · 2024Pooled it
- Noninvasive malaria detection beyond blood sampling.Sensors & diagnostics · 2026Review
- [Variability in urban malaria transmission across health districts in Bouaké, Côte d'Ivoire].Medecine tropicale et sante internationale · 2026Article
- Attitude and practices of district-level HMIS managers towards malaria routine reporting in Uganda: a 2024 cross-sectional study.Malaria journal · 2026Article
- High resolution physically based modelling reveals malaria incidence reduction by vector control measures.Scientific reports · 2026Article
- Model-guided geospatial surveillance system for antimalarial drug resistance.PLOS global public health · 2026Article
- Reinventing malaria control: hierarchical intervention strategies for African settings based on the microbiota-barrier-innate immunity axis.Frontiers in immunology · 2026Review
- PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse immunogenicity studies.Human vaccines & immunotherapeutics · 2025Article
- Experimental models of liver-stage malaria: Progress, gaps, and challenges.PLoS pathogens · 2025Review
- Comparative serum proteomics of plasmodium-infected free-living macaques in Thailand: Host immune responses and candidate biomarkers for zoonotic malaria.Veterinary world · 2025Article
- Article
- Emerging Molecular Mechanisms in Malaria Pathogenesis and Novel Therapeutic Approaches: A Focus onBiomolecules · 2025Review
- The association between infrastructure damage in the aftermath of Cyclone Idai and malaria risk in Sofala Province, Mozambique: an ecological study.Malaria journal · 2024Article
- Beyond Crop-Raiding: Unravelling the Broader Impacts of Human-Wildlife Conflict on Rural Communities.Environmental management · 2024Article
- Modeling resource allocation strategies for insecticide-treated bed nets to achieve malaria eradication.eLife · 2024Article
- Dynamics of malaria vector composition and Plasmodium falciparum infection in mainland Tanzania: 2017-2021 data from the national malaria vector entomological surveillance.Malaria journal · 2024Article
- Article
- Burden and seasonal distribution of malaria in Ziquala district, Northeast Ethiopia: a 5-year multi-centre retrospective study.BMJ open · 2023Article
- Genome-wide genetic variation and molecular surveillance of drug resistance in Plasmodium falciparum isolates from asymptomatic individuals in Ouélessébougou, Mali.Scientific reports · 2023Article
- Using antenatal care as a platform for malaria surveillance data collection: study protocol.Malaria journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAccess to malaria control interventions falls short of universal health coverage. The Global Technical Strategy for malaria targets at least 90% reduction in case incidence and mortality rates, and elimination in 35 countries by 2030. The potential to reach these targets will be determined in part by investments in malaria. This study estimates the financing required for malaria control and elimination over the 2016-2030 period.
methodsA mathematical transmission model was used to explore the impact of increasing intervention coverage on burden and costs. The cost analysis took a public provider perspective covering all 97 malaria endemic countries and territories in 2015. All control interventions currently recommended by the WHO were considered. Cost data were sourced from procurement databases, the peer-reviewed literature, national malaria strategic plans, the WHO-CHOICE project and key informant interviews.
resultsAnnual investments of $6.4 billion (95% uncertainty interval (UI $4.5-$9.0 billion)) by 2020, $7.7 billion (95% UI $5.4-$10.9 billion) by 2025 and $8.7 billion (95% UI $6.0-$12.3 billion) by 2030 will be required to reach the targets set in the Global Technical Strategy. These are equivalent to annual investment per person at risk of malaria of US$3.90 by 2020, US$4.30 by 2025 and US$4.40 by 2030, compared with US$2.30 if interventions were sustained at current coverage levels. The 20 countries with the highest burden in 2015 will require 88% of the total investment.
conclusionsGiven the challenges in increasing domestic and international funding, the efficient use of currently available resources should be a priority.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.